Compass Pathways announces the launch of a Phase II clinical trial using psilocybin-based COMP360 as a treatment for anorexia nervosa.
VIEW IN BROWSER
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
Compass Pathways announces the launch of a Phase II clinical trial using psilocybin-based COMP360 as a treatment for anorexia nervosa. |
Learn More
Red Light Holland to Acquire Two Wellness Shops in the Netherlands: SmartShop Utrecht and SmartShop OSS
Red Light Holland acquires two of the Netherlands premier shops for psychedelic truffles and wellness products. |
Find out more
Pasithea Therapeutics Awarded a Drug Development Research Grant
Pasithea Therapeutics announces being awarded a research grant of AUD $1 million (US$694,000) for its psychedelics-based research for ALS disease. |
Read more
TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260
info@theseedinvestor.com
©2019, All Rights Reserved
|
Unsubscribe
|
View this in Browser
To keep receiving emails from us, please add us to your address book.